In order to provide a pre-clinical rationale for the design of new therapeutic strategies for patients diagnosed with PCNSL, herein we evaluate the role of XPO1 and BTK inhibition in intracerebral xenograft murine models, focusing on malignant cells and the innate immune microenvironment. Here, BTK is linked to primary central nervous system lymphoma.